Biography

Prof Yongjun Wang is the President of Beijing Tiantan Hospital, Capital Medical University, and a Professor of Neurology. He serves as Director of the National Center for Healthcare Quality Management in Neurological Diseases, Deputy Director of the National Center for Clinical Research in Neurological Diseases, and Director of the Beijing Advanced Innovation Center for Brain Protection.

Prof Wang is an Academician of the Chinese Academy of Sciences and a member of the Academic Advisory Committee of the Chinese Academy of Medical Sciences. He is also a "Beijing Scholar" and a renowned expert in neurology. He serves as President of the Chinese Stroke Association, Chairman of the Neurology Branch of the Chinese Medical Association, and Editor-in-Chief of the journal "Stroke & Vascular Neurology."

He has served as Chief Expert of the cerebrovascular disease field for the National 12th Five-Year Science and Technology Support Program, Chief Expert of the non-communicable chronic disease field for the National 13th Five-Year Key R&D Program, and a member of the Expert Committee for the National Major New Drug Creation Science and Technology Major Project.

Prof Wang has been working on the front lines of cerebrovascular disease clinical practice, research, and prevention for decades. He proposed that the key to cerebrovascular disease prevention and control lies in the "high-risk non-disabling" population, constructing a new risk prediction model that solves the clinical challenge of identifying high-risk patients. He pioneered the CHANCE (Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events) therapy, a short-term dual-channel dual-effect combination treatment method for cerebrovascular disease, which has rewritten global cerebrovascular disease guidelines and reduced patient recurrence risk by 32%. He discovered pharmacogenetic factors affecting the CHANCE therapy and created personalized precision medicine protocols, further reducing recurrence risk by 20%.

He has revealed the mechanisms of residual recurrence risk in cerebrovascular disease, developed therapeutic drugs targeting new mechanisms and targets, and achieved industrialization. He has published over 200 papers as first or corresponding author in journals including NEJM, JAMA, BMJ, and Circulation. Large-scale clinical studies in which he participated in designing and served as a primary contributor account for 30% of all cerebrovascular disease research articles published in NEJM during the same period.